The Joint Corp. (JYNT) Tops Q4 EPS by 3c, provides guidance

The Joint Corp. (NASDAQ: JYNT) reported Q4 EPS of $0.07, $0.03 better than the analyst estimate of $0.04. Revenue for the quarter came in at $15.2 million versus the consensus estimate of $14.29 million.

2026 Guidance
The Company provided the following guidance for 2026.

System-wide sales are expected to be between $519 million and $552 million, compared to $532.4 million in 2025.
System-wide comp sales for clinics open 13 months or more are expected to be in the range of (3)% to 3%, compared to (0.4)% in 2025.
Consolidated Adjusted EBITDA is expected to be in the range of $12.5 and $13.5 million, compared to $13.0 million in 2025.
New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be in the range of 30 to 35, compared to 29 in 2025. The Company is working with franchise owners to optimize the performance of the existing franchised clinic base. This may include closing underperforming clinics this year and may result in the overall clinic count at 2026 year end being lower than 2025 year end.

For earnings history and earnings-related data on The Joint Corp. (JYNT) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• ZenaTech raises Plurilock Security stake to 12% with new share purchase
• A.O. Smith executive chairman to retire, CEO to assume chairman role